Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "MEA"

1407 News Found

Vakrangee partners with PharmEasy to deliver medicines to remote areas
Digitisation | December 16, 2021

Vakrangee partners with PharmEasy to deliver medicines to remote areas

Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country


Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures
Biotech | November 09, 2021

Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures

Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries


DSM increases price for polyamide 6 and 66 in EMEA
News | March 02, 2021

DSM increases price for polyamide 6 and 66 in EMEA

The price increases are due to the rising costs of raw materials.


Sanofi secures two breakthrough nods in China for rare blood disorders
News | December 16, 2025

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia


Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial
Clinical Trials | December 13, 2025

Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial

Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%


EMA backs Eylea 8 mg for retinal vein occlusion
News | December 13, 2025

EMA backs Eylea 8 mg for retinal vein occlusion

The positive CHMP opinion is supported by results from the Phase III QUASAR trial


Merck wins key EU backing to expand use of PAH Drug WINREVAIR
News | December 13, 2025

Merck wins key EU backing to expand use of PAH Drug WINREVAIR

WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states


Suven Life Sciences achieved 100% patient enrolment in Phase-2b clinical trial of Ropanicant for MDO
Clinical Trials | December 12, 2025

Suven Life Sciences achieved 100% patient enrolment in Phase-2b clinical trial of Ropanicant for MDO

The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA


GSK’s experimental lung cancer drug gains FDA orphan drug status
Drug Approval | December 12, 2025

GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization